Atea Pharmaceuticals (AVIR) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

AVIR · Stock Price

USD 5.54+2.58 (+87.16%)

Market Cap: $442.5M

Historical price data

Market Cap: $442.5MPipeline: 24 drugs (3 Phase 3)Patents: 20Founded: 2014Employees: 100-250HQ: Boston, United States

Sector Ranking#216 in Small Molecule Drugs

Overview

Atea Pharmaceuticals is a Boston-based biotech focused on discovering and developing oral antiviral therapies for RNA viruses, leveraging a proprietary platform of purine nucleos(t)ide prodrugs. Its lead asset, a combination of bemnifosbuvir (polymerase inhibitor) and ruzasvir (NS5A inhibitor), is in Phase 3 development for hepatitis C with topline data expected in 2026. Founded by antiviral veteran Jean-Pierre Sommadossi, the company's strategy targets significant unmet needs in HCV and other RNA viral diseases with convenient oral regimens designed for high efficacy and a high barrier to resistance.

Hepatitis CHepatitis EViral Infections

Technology Platform

Proprietary platform of purine nucleos(t)ide prodrugs designed to inhibit the highly conserved viral RNA-dependent RNA polymerase (RdRp), enabling oral therapies with a high barrier to resistance for RNA viruses.

Pipeline

24

24 drugs in pipeline3 in Phase 3

Drug	Indication	Stage
Bemnifosbuvir (BEM) + Placebo	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2 Infection)	Phase 3
Bemnifosbuvir-Ruzasvir (BEM/RZR) + Sofosbuvir-Velpatasvir (S...	HEPATITIS C VIRUS CHRONIC INFECTION	Phase 3
Bemnifosbuvir-Ruzasvir + Sofosbuvir-Velpatasvir	HEPATITIS C VIRUS CHRONIC INFECTION	Phase 3
Bemnifosbuvir + Ruzasvir	Chronic Hepatitis C Virus	Phase 2
AT-752 + Placebo	Dengue Fever	Phase 2

Funding History

3

Total raised:$545M

IPO$300MUndisclosedOct 15, 2020

Series B$215MF-Prime CapitalJun 15, 2019

Series A$30MF-Prime CapitalMay 15, 2014

Opportunities

Atea's lead HCV regimen targets specific unmet needs within a large, enduring market, including patients with advanced liver disease and those seeking a short-duration, protease inhibitor-free option.

Success could also validate its platform for expansion into other RNA viral diseases like hepatitis E, where there are no approved therapies.

Risk Factors

The company faces binary risk from its Phase 3 HCV trial readouts in 2026; failure would be catastrophic.

Even with approval, commercializing in a mature, competitive market dominated by large pharma presents a significant challenge, and the company will require substantial additional capital.

Competitive Landscape

Atea competes in HCV against entrenched leaders Gilead and AbbVie, who offer highly effective standard-of-care regimens. Its primary differentiation is a protease inhibitor-free, 8-week regimen aimed at niche populations. The growing threat of generics later this decade adds complexity to the commercial landscape.